Roni Mamluk, PhD is the CEO of Ayala Pharmaceuticals a clinical-stage precision oncology company. She is a senior biopharmaceutical executive with 14 years experience in drug development companies and background in all aspects of R&D, general management and fund raising.

Prior to Ayala Roni was at Chiasma (CHMA) a biopharmaceuticals company focused on orphan diseases where she fulfilled multiple positions including CEO (2013-2015). She is an inventor of their oral delivery technology, led the development of their lead product through all stages of development, including NDA submission.

She was a key player in fund raising for the company including several private financing rounds and led a $70M cross over financing and a successful IPO of over $100M in 2015.

Roni is now a board member at Chiasma. Prior to that she was heading preclinical development of an oncology product at Adnexus (which was later acquired by BMS) in Waltham, MA and prior to that did her post doc at Children’s hospital/Harvard medical school in the field of angiogenesis. Roni received her PhD, summa cum laude from the Hebrew University in Jerusalem.